| Literature DB >> 32845850 |
Yeye Guo1,2,3, Minxue Shen1,2,3,4, Xiang Chen1,2,3, Juan Su1,2,3, Xu Zhang1,2,3, Yi Xiao1,2,3, Shuang Zhao1,2,3, Mingzhu Yin1,2,3, Wenbo Bu5, Yan Wang5.
Abstract
BACKGROUND: The outbreak of COVID-19 has profoundly influenced people's lifestyles; these impacts have varied across subgroups of people. The pandemic-related impacts on the health outcomes of people with dermatological conditions are unknown.Entities:
Keywords: COVID-19; coronavirus disease 2019; dermatology; impact; isolation; lifestyle; outcome; quality of life; skin diseases; survey; unemployment; web-based
Mesh:
Year: 2020 PMID: 32845850 PMCID: PMC7490117 DOI: 10.2196/22288
Source DB: PubMed Journal: J Med Internet Res ISSN: 1438-8871 Impact factor: 5.428
Characteristics of the participants (N=506).
| Characteristic | Value | |
| Age (years), mean (SD) | 33.5 (14.0) | |
|
| ||
|
| Male | 217 (42.9) |
|
| Female | 289 (57.1) |
|
| ||
|
| Unmarried | 189 (37.4) |
|
| Married | 291 (57.5) |
|
| Widowed | 22 (4.3) |
|
| Divorced | 4 (0.8) |
|
| ||
|
| Primary school and below | 49 (9.7) |
|
| Middle school | 69 (13.6) |
|
| High school | 82 (16.2) |
|
| College and above | 306 (60.5) |
|
| ||
|
| <10,000 | 155 (30.6) |
|
| 10,000-49,999 | 132 (26.1) |
|
| 50,000-99,999 | 122 (24.1) |
|
| ≥100,000 | 97 (19.2) |
|
| ||
|
| Infectious skin diseases | 57 (11.3) |
|
| Papulosquamous disorders | 58 (11.5) |
|
| Allergic skin diseases | 103 (20.4) |
|
| Disorders of appendages | 46 (9.1) |
|
| Disorders of hairs | 36 (7.1) |
|
| Pigmentary disorders | 38 (7.5) |
|
| Skin tumors | 30 (5.9) |
|
| Other | 189 (37.4) |
|
| ||
|
| <1 | 202 (39.9) |
|
| 1-5 | 165 (32.6) |
|
| 6-10 | 57 (11.3) |
|
| >10 | 82 (16.2) |
|
| ||
|
| Outdoor activity unrestricted | 252 (49.8) |
|
| Outdoor activity partly restricted | 126 (24.9) |
|
| Isolated at home or in hospital | 128 (25.3) |
|
| ||
|
| Unaffected | 189 (37.4) |
|
| Reduced | 208 (41.1) |
|
| Completely lost | 109 (21.5) |
|
| ||
|
| Adherent to treatment | 121 (23.9) |
|
| No treatment prescribed | 210 (41.5) |
|
| Not adherent to treatment | 175 (34.6) |
|
| ||
|
| Visited a physician in hospital | 126 (24.9) |
|
| Consulted a doctor remotely | 92 (18.2) |
a1 ¥ = US $0.15.
Associations of epidemic-related impacts with patient-reported outcome scores of skin diseases (N=506).
| Exposure group | Stress VASa | PHQ-9b | GAD-7c | DLQId | Health utility | |||||||||||
|
|
| Mean SE | Mean SE | Mean SE | Mean SE | Mean SE | ||||||||||
|
| ||||||||||||||||
|
| Unaffected | 4.05 (0.18) | Ref e | 4.56 (0.30) | Ref | 3.31 (0.26) | Ref | 5.47 (0.41) | Ref | 0.96 (0.01) | Ref | |||||
|
| Restricted | 4.56 (0.26) | .10 | 6.33 (0.42) | <.001 | 4.97 (0.37) | .001 | 6.13 (0.58) | .35 | 0.93 (0.01) | .02 | |||||
|
| Isolated | 4.38 (0.25) | .30 | 5.77 (0.42) | .02 | 4.20 (0.37) | .049 | 7.11 (0.58) | .02 | 0.93 (0.01) | .02 | |||||
|
| ||||||||||||||||
|
| Unaffected | 3.23 (0.20) | Ref | 4.17 (0.34) | Ref | 3.19 (0.30) | Ref | 4.85 (0.47) | Ref | 0.96 (0.01) | Ref | |||||
|
| Reduced | 4.54 (0.19) | <.001 | 5.77 (0.32) | .001 | 4.19 (0.29) | .02 | 6.18 (0.45) | .04 | 0.94 (0.01) | .051 | |||||
|
| Completely lost | 5.50 (0.26) | <.001 | 6.39 (0.45) | <.001 | 4.79 (0.40) | .002 | 7.87 (0.62) | <.001 | 0.92 (0.01) | <.001 | |||||
|
| ||||||||||||||||
|
| Unaffected | 3.91 (0.14) | Ref | 4.84 (0.23) | Ref | 3.60 (0.21) | Ref | 5.28 (0.32) | Ref | 0.95 (0.00) | Ref | |||||
|
| Unemployed | 5.64 (0.28) | <.001 | 7.15 (0.46) | <.001 | 5.30 (0.41) | <.001 | 9.10 (0.63) | <.001 | 0.91 (0.01) | <.001 | |||||
|
| ||||||||||||||||
|
| Adherent | 4.75 (0.26) | Ref | 5.64 (0.43) | Ref | 3.59 (0.38) | Ref | 6.24 (0.58) | Ref | 0.93 (0.01) | Ref | |||||
|
| No treatment needed | 3.94 (0.20) | .01 | 4.41 (0.32) | .02 | 3.30 (0.29) | .54 | 4.12 (0.44) | <.001 | 0.97 (0.01) | <.001 | |||||
|
| Nonadherent | 4.30 (0.22) | .18 | 6.14 (0.36) | .37 | 4.97 (0.31) | .005 | 8.23 (0.48) | .008 | 0.93 (0.01) | .75 | |||||
aVAS: Visual Analog Scale.
bPHQ-9: Patient Health Questionnaire-9.
cGAD-7: Generalized Anxiety Disorder-7.
dDLQI: Dermatology Life Quality Index.
e Ref: reference group.
Associations of epidemic-related impacts with patient-reported outcomes of skin diseases (N=506).
| Exposure group | Perceived stress | Depression | Anxiety | Impaired quality of life | |||||||||
|
|
| aORe,f | 95% CI | aOR | 95% CI | aOR | 95% CI | aOR | 95% CI | ||||
|
| |||||||||||||
|
| Unaffected | Refg | N/Ah | N/A | Ref | N/A | N/A | Ref | N/A | N/A | Ref | N/A | N/A |
|
| Restricted | 0.90 | 0.52-1.56 | .71 | 1.36 | 0.84-2.21 | .21 | 1.39 | 0.73-2.64 | .31 | 1.22 | 0.70-2.12 | .48 |
|
| Isolated | 1.02 | 0.59-1.77 | .93 | 1.81 | 1.13-2.89 | .013 | 2.20 | 1.23-3.96 | .008 | 1.78 | 1.05-3.01 | .03 |
|
| |||||||||||||
|
| Unaffected | Ref | N/A | N/A | Ref | N/A | N/A | Ref | N/A | N/A | Ref | N/A | N/A |
|
| Reduced | 1.59 | 0.91-2.79 | .10 | 2.22 | 1.38-3.57 | .001 | 1.64 | 0.88-3.06 | .12 | 1.27 | 0.73-2.20 | .40 |
|
| Complete loss | 4.05 | 2.13-7.72 | <.001 | 2.56 | 1.43-4.58 | .002 | 2.48 | 1.19-5.13 | .02 | 2.62 | 1.40-4.92 | .003 |
|
| |||||||||||||
|
| Unaffected | Ref | N/A | N/A | Ref | N/A | N/A | Ref | N/A | N/A | Ref | N/A | N/A |
|
| Unemployed | 2.41 | 1.42-4.08 | .001 | 2.11 | 1.30-3.43 | .003 | 2.60 | 1.45-4.65 | .001 | 2.59 | 1.54-4.35 | <.001 |
|
| |||||||||||||
|
| Adherent | Ref | N/A | N/A | Ref | N/A | N/A | Ref | N/A | N/A | Ref | N/A | N/A |
|
| No treatment needed | 0.81 | 0.461.41 | .45 | 0.86 | 0.52-1.44 | .26 | 0.66 | 0.33-1.29 | .22 | 0.58 | 0.32-1.04 | .07 |
|
| Nonadherent | 0.81 | 0.46-1.42 | .46 | 1.39 | 0.84-2.31 | .68 | 1.39 | 0.75-2.58 | 0.297 | 1.35 | 0.78-2.33 | .29 |
aVAS: Visual Analog Scale.
bPHQ-9: Patient Health Questionnaire-9.
cGAD-7: Generalized Anxiety Disorder-7.
dDLQI: Dermatology Life Quality Index.
eaOR: adjusted odds ratio.
fAdjusted for age, gender, income, and educational level.
gRef: reference group.
hN/A: not applicable.